Salimi M, Spinelli J J
Kermanshah University of Medical Science, Iran.
Am J Clin Oncol. 1996 Feb;19(1):18-22. doi: 10.1097/00000421-199602000-00004.
Retrospectively, 41 Iranian patients with Mediterranean abdominal lymphoma (MAL) were studied; 21 patients had received anthracycline-based protocols, and 20 patients had been treated with regimens lacking anthracyclines. The study groups were comparable with respect to several factors, including age, performance status, histology of lymphoma, stage of disease, and the average relative dose intensity of their protocols. Our first group had a complete remission (CR) rate of 62%, mean disease-free interval (DFI) of 16.3 months and a 71% overall survival at 30 months. The second group showed a CR rate of 40%, mean DFI of 11.2 months, and a 35% overall survival at 30 months. The differences were significant in survival (P = .012) and DFI (p < .001). The incidence of serious toxicities and complications was similar.
我们回顾性研究了41例患有地中海腹部淋巴瘤（MAL）的伊朗患者；21例患者接受了含蒽环类药物的方案治疗，20例患者接受了不含蒽环类药物的方案治疗。研究组在几个因素方面具有可比性，包括年龄、体能状态、淋巴瘤组织学类型、疾病分期以及其方案的平均相对剂量强度。我们的第一组完全缓解（CR）率为62%，平均无病生存期（DFI）为16.3个月，30个月时总生存率为71%。第二组CR率为40%，平均DFI为11.2个月，30个月时总生存率为35%。生存率（P = 0.012）和DFI（P < 0.001）的差异具有统计学意义。严重毒性和并发症的发生率相似。
